3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
20
Lymphoma
6
Urinary Bladder Neoplasms
3
Urothelial Carcinoma of the Bladder
1
Rhabdoid Tumor
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Choroid Plexus Neoplasms
1
Childhood Solid Tumor
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Astrocytoma
1
Interventions
Cisplatin
15
Pemetrexed
12
pembrolizumab
9
Carboplatin
8
Nivolumab
7
Cyclophosphamide
6
Platinum
5
Ipilimumab
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
3
Radiotherapy, Intensity-Modulated
3
Interleukin-2
3
Gemcitabine
3
tremelimumab
2
durvalumab
2
atezolizumab
2
aldesleukin
2
Radiotherapy
2
Radiation
2
Photochemotherapy
2
Pharmaceutical Preparations
2
Methotrexate
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
Cerebral Decortication
2
nintedanib
1
methoxyamine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
cediranib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Vinblastine
×
1 year
×
Clear all
No trials found.